Stocks and Investing
Stocks and Investing
Tue, April 12, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Robert Burns Maintained (BNTX) at Strong Buy with Decreased Target to $298 on, Apr 12th, 2022
Robert Burns of HC Wainwright & Co., Maintained "BioNTech SE" (BNTX) at Strong Buy with Decreased Target from $339 to $298 on, Apr 12th, 2022.
Robert has made no other calls on BNTX in the last 4 months.
There are 3 other peers that have a rating on BNTX. Out of the 3 peers that are also analyzing BNTX, 2 agree with Robert's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Emmanuel Papadakis of "Deutsche Bank" Maintained at Hold and Held Target at $200 on, Friday, April 1st, 2022
- Simon Baker of "Redburn Partners" Upgraded from Strong Sell to Hold on, Tuesday, February 1st, 2022
This is the rating of the analyst that currently disagrees with Robert
- Arlinda Lee of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $300 on, Tuesday, April 5th, 2022
Contributing Sources